About
OligoTune develops proprietary RNA oligonucleotide therapeutics designed to disrupt pathways that enable solid tumours to evade immune responses, aiming to improve the effectiveness and accessibility of cancer immunotherapy.
Explore OligoTune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.